Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01643226 · ClinicalTrials.gov registry record · Phase 3

Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus

A Phase 3 study, sponsored by Glaukos Corporation.

Completed
Registry status
Phase 3
Development phase
230
Enrollment target

NCT01643226: Completed Phase 3 study, sponsored by Glaukos Corporation.

NCT01643226 is a Phase 3 study that has completed, run by Glaukos Corporation. The registered enrollment target is 230 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01643226, a Phase 3 study, has completed, sponsored by Glaukos Corporation.

COMPLETED
Registry status
Phase 3
Development phase
230 participants
Enrollment target

Study Summary

The objectives of this study are to evaluate the safety and efficacy of corneal collagen cross-linking performed with VibeX (riboflavin ophthalmic solution) and the KXL System as compared to placebo in impeding the progression of, and/or reducing, maximum corneal curvature.

Interventions

  • DRUG riboflavin solution
  • DRUG placebo solution
  • DEVICE KXL System

Trial Details

FieldValue
Enrollment Target 230 participants
Start Date 2012-07
Est. Completion 2016-09
Phase Phase 3
Glaukos Corporation

33 total trials

What the finished NCT01643226 record still lists

NCT01643226 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower).

The record links to 0 conditions, and to 3 interventions - of which riboflavin solution is the first listed.

NCT01643226 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01643226 about?

NCT01643226 is a clinical study titled "Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus". The objectives of this study are to evaluate the safety and efficacy of corneal collagen cross-linking performed with VibeX (riboflavin ophthalmic solution) and the KXL System as compared to placebo in impeding the progression of, and/or reducing, maximum corneal curvature.

What is the current status of trial NCT01643226?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 230 participants. The study started on 2012-07. Estimated completion is 2016-09.

What interventions are being tested in trial NCT01643226?

The interventions under investigation include: riboflavin solution (DRUG), placebo solution (DRUG), KXL System (DEVICE).

Who is sponsoring clinical trial NCT01643226?

This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01643226's enrollment target sits among peer trials

230 1304th of 2000 higher than 692 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02710253 · 230 participants · Phase 2

    Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy

  • NCT02777879 · 230 participants

    Lung Microbiome and Inflammation in Early COPD

  • NCT03824483 · 230 participants · Phase 2

    Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

  • NCT03833622 · 230 participants · NA

    Shared Decision Making to Improve Goals of Care in the ED

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01643226, the US trial registry maintained by the National Library of Medicine. NCT01643226 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.